TOP - February 2017, Vol 10, No 1

Anticancer drugs should be priced based on the value they deliver to patients, according to Peter B. Bach, MD, Physician, Epidemiologist, Researcher, and Director, Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center, New York.
Pharmacy-led oral chemotherapy programs lead to improved patient adherence and satisfaction, according to Benyam Muluneh, PharmD, BCOP, CPP, Oncology Clinical Pharmacist Practitioner, University of North Carolina (UNC) Medical Center, Malignant Hematology Clinic, Chapel Hill.
  • Gaps in Use of Tyrosine Kinase Inhibitors in Medicare Beneficiaries with Chronic Myeloid Leukemia
  • Ricolinostat Shows Promise in Patients with Relapsed or Refractory Multiple Myeloma
Although the prevalence of high-grade, aggressive non-Hodgkin lymphoma increases with age, survival outcomes for older patients are disproportionately inferior to those for younger patients.
Including both children and adults, the American Cancer Society’s estimates for 2016 predict approximately 6590 new cases of ALL (3590 in males and 3000 in females) and approximately 1430 deaths (800 in males and 630 in females) attributable to the disease.
Although the prevalence of high-grade, aggressive non-Hodgkin lymphoma increases with age, survival outcomes for older patients are disproportionately inferior to those for younger patients.
Adherence to infusional or injectable anticancer drugs is not problematic—as long as the patient gets the infusion or injection, adherence is assured—but adherence is an emerging problem with newer oral anticancer drugs.
Targeted agents and immunotherapy are displacing chemotherapy in certain subgroups of the treatment of lung cancer, but chemotherapy remains a key therapeutic pillar in the daily management of patients with this disease, according to Jean-Charles Soria, MD, PhD, Head of the Drug Development Department, Gustave Roussy, Villejuif, France.
Page 3 of 3
Results 21 - 28 of 28